Show simple item record

dc.contributor.authorTorres Sánchez, Sonia 
dc.contributor.authorda Silva Borges, Gisela
dc.contributor.authorMicó Segura, Juan Antonio 
dc.contributor.authorBerrocoso Domínguez, Esther María 
dc.contributor.otherNeurocienciases_ES
dc.contributor.otherPsicologíaes_ES
dc.date.accessioned2025-01-24T18:53:17Z
dc.date.available2025-01-24T18:53:17Z
dc.date.issued2018-01
dc.identifier.issn0028-3908
dc.identifier.urihttp://hdl.handle.net/10498/34761
dc.description.abstractTapentadol is an analgesic that acts as an agonist of µ opioid receptors (MOR) and that inhibits noradrenaline reuptake. Data from healthy rats show that tapentadol inhibits neuronal activity in the locus coeruleus (LC), a nucleus regulated by both the noradrenergic and opioid systems. Thus, we set out to investigate the effect of tapentadol on LC activity in streptozotocin (STZ)-induced diabetic rats, a model of diabetic polyneuropathy, by analyzing single-unit extracellular recordings of LC neurons. Four weeks after inducing diabetes, tapentadol dose-response curves were obtained from animals pre-treated with RX821002 or naloxone (alpha2-adrenoceptors and opioid receptors antagonists, respectively). In STZ rats, the spontaneous activity of LC neurons (0.9 ± 0.1 Hz) was lower than in naïve animals (1.5 ± 0.1 Hz), and tapentadol's inhibitory effect was also weaker. Alpha2-adrenoceptors blockade by RX821002 (100 μg/kg i.v.) in STZ animals significantly increased the spontaneous activity (from 0.8 ± 0.1 to 1.4 ± 0.2 Hz) and it dampened the inhibition of LC neurons produced by tapentadol. However, opioid receptors blockade following naloxone pre-treatment (5 mg/kg i.v.) did not alter the spontaneous firing rate (0.9 ± 0.2 vs 0.9 ± 0.2 Hz) or the inhibitory effect of tapentadol on LC neurons in STZ animals. Thus, diabetic polyneuropathy appears to exert neuroplastic changes in LC neurotransmission, enhancing the sensitivity of alpha2-adrenoceptors and dampening opioid receptors expression. Tapentadol's activity seems to be predominantly mediated through its noradrenergic effects rather than its influence on opioid receptors in the STZ model of diabetic polyneuropathy.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceNeuropharmacology. 2018 Jun;135:202-210.es_ES
dc.subjectLocus coeruleuses_ES
dc.subjectNeuropathic paines_ES
dc.subjectOpioid receptores_ES
dc.subjectStreptozotocines_ES
dc.subjectTapentadoles_ES
dc.subjectalpha2-adrenoceptores_ES
dc.titleOpioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain.es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsclosed accesses_ES
dc.identifier.doi10.1016/j.neuropharm.2018.03.014
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional